Evidence map›Paper›PMID 33747370›Full record

ArticleJournal of extracellular vesicles2021

Engineered extracellular vesicles as versatile ribonucleoprotein delivery vehicles for efficient and safe CRISPR genome editing.

Xingang Yao, Pin Lyu, Kyung Yoo, Manish Kumar Yadav, Ravi Singh, Anthony Atala, Baisong Lu

Open access · goldAbstract read
In one paragraph

Article in Journal of extracellular vesicles, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers.

0numbers the graph read from it
0cells of the map it votes in
123citing papers in PubMed
11.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

123 citing papers in PubMed, 187 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Restoration of the immune system with base editing and non-genotoxic conditioning in a Rag2 point-mutant mouse model.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  6. Review
  7. Endogenous Engineering Reprograms Extracellular Vesicles for Enhanced Therapeutic Function.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Frontiers in immunology · 2026
    Review
  20. Review

63 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Xingang YaoWake Forest Institute for Regenerative Medicine Wake Forest University Health Sciences Winston-Salem North Carolina USA.
Pin LyuWake Forest Institute for Regenerative Medicine Wake Forest University Health Sciences Winston-Salem North Carolina USA.
Kyung YooWake Forest Institute for Regenerative Medicine Wake Forest University Health Sciences Winston-Salem North Carolina USA.
Manish Kumar YadavWake Forest Institute for Regenerative Medicine Wake Forest University Health Sciences Winston-Salem North Carolina USA.
Ravi SinghDepartment of Cancer Biology Wake Forest University Health Sciences Winston-Salem North Carolina USA.
Anthony AtalaWake Forest Institute for Regenerative Medicine Wake Forest University Health Sciences Winston-Salem North Carolina USA.
Baisong LuWake Forest Institute for Regenerative Medicine Wake Forest University Health Sciences Winston-Salem North Carolina USA.
Wake Forest University · USForest Institute · US

Funding

Development of a novel therapeutic agent that exploits specific vulnerabilities in claudin low breast cancerR01CA207222 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SINGH, RAVI N · 2017 to 2021
$1.7M
NCI NIH HHS R01 CA207222
6 · The paper itself

Abstract

Transient delivery of CRISPR-based genome editing effectors is important to reduce off-target effects and immune responses. Recently extracellular vesicles (EVs) have been explored for Cas9 ribonucleoprotein (RNP) delivery. However, lack of mechanisms to enrich RNPs into EVs limited the efficiency of EVs as a RNP delivery vehicle. Here we describe a mechanism to actively enrich RNPs into EVs. We used the specific interaction between RNA aptamer and aptamer-binding protein (ABP) to enrich RNPs into EVs. We inserted RNA aptamer com into single guide RNA (sgRNA), and fused com-binding ABP Com to both termini of tetraspan protein CD63 that is abundant in exosomes. We found that the Com/com interaction enriched Cas9 and adenine base editor (ABE) RNPs into EVs, via forming a three-component complex including CD63-Com fusion protein, com-modified sgRNA and Cas9 or ABE. The RNP enriched EVs are efficient in genome editing and transiently expressed. The system is capable of delivering RNPs targeting multiple loci for multiplex genome editing. In addition, Cas9 from different species can be used together. The EV-delivered RNPs are active in vivo. The data show that the aptamer and ABP interactions can be utilized to actively enrich RNPs into EVs for improved genome editing efficiency and safety.

Indexed as

Cell EngineeringClustered Regularly Interspaced Short Palindromic RepeatsExtracellular VesiclesPharmaceutical VehiclesRibonucleoproteinsAnimalsFemaleGene EditingHEK293 CellsHumansMiceTetraspanin 30Pharmaceutical VehiclesRibonucleoproteinsTetraspanin 30adenine base editoraptameraptamer‐binding proteinCD63CRISPR/Cas9deliveryextracellular vesicleribonucleoprotein

Identifiers

PMID33747370
PMCPMC7962171
OpenAlexW3138127439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.